The Integrated Development and Manufacturing Organization: The Future of Cell Therapy Manufacturing

  • Introducing the Integrated Development and Manufacturing Organization (IDMO)
  • Integrating technology and manufacturing services to overcome manufacturing bottlenecks and meet global cell therapy patient demand
  • Automating cell therapy manufacture to increase flexibility, decrease manufacturing costs, improve quality, and increase capacity
  • Join the IDMO revolution

John Tomtishen
VP Operations

John Tomtishen is Vice President of Operations at Cellares Corporation. At Cellares, John is responsible for Cellares’ IDMO business, supporting partnership activities, and facilitating accelerated market adoption of Cellares’ Cell Shuttle technology to transform the cell therapy manufacturing paradigm and address industry bottlenecks to accelerate access to life saving cell therapies. John has extensive experience in cell and gene therapies, biologics, and vaccines with diverse roles in Business Operations, CMC/Technical Operations, R&D, Supply Chain, Engineering/Facilities, and Operational Excellence. While at Novartis Pharmaceuticals, John had an integral role in the filing and approval of the first CAR T-cell BLA, Kymriah™ (tisagenlecleucel) for pALL (pediatric acute lymphoblastic leukemia) and DLBCL (diffuse large B-cell lymphoma). While at Legend Biotech, John had direct oversight over Legend’s CMC strategy, US Operations, Ex-US Expansion into Europe, and provided support to Legend’s teams in China. In addition, John had an integral role in the clinical development and BLA filing of Carvykti™ (ciltacabtagene autoleucel) for MM (multiple myeloma) in collaboration with Janssen Pharmaceuticals.

Cellares is creating the future of cell therapy manufacturing and accelerating access to life-saving cell therapies. The company is developing a one-of-a-kind solution to overcome the limitations associated with manufacturing cell therapies that are more affordable and widely available to patients in need. With Cellares’ proprietary platform—the Cell Shuttle—biopharma companies, academic research centers, and CDMOs will no longer have to compromise by either choosing a manufacturing platform that is semi-automated but lacks workflow flexibility, or one that provides customization but not the end-to-end automation needed to manufacture at scale. The company is headquartered in South San Francisco, Calif.